Zobrazeno 1 - 10
of 463
pro vyhledávání: '"ER+"'
Autor:
Alishbah Saddiqa, Mahrukh Zakir, Mawara Sheikh, Zahid Muneer, Arsalan Hassan, Iqra Ali, Ihtisham Ul Haq, Azmat Ali Khan, Abdul Malik, Abdul Rauf Siddiqi
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-15 (2024)
Abstract Breast cancer (BC) is a malignant neoplasm which is classified into various types defined by underlying molecular factors such as estrogen receptor positive (ER+), progesterone receptor positive (PR+), human epidermal growth factor positive
Externí odkaz:
https://doaj.org/article/01c6d4dda43b443b8073afc05e56771c
Autor:
Juan Yang, Yin Li, Xiao Han, Tianjiao Li, Ding Li, Qiao Liu, Lizhong Yan, Fei Li, Xiaolin Pei, Ya Feng, Zhoujun Lin, Zhenkun Fu, Changjun Wang, Qiang Sun, Chenggang Li
Publikováno v:
Biochemistry and Biophysics Reports, Vol 38, Iss , Pp 101706- (2024)
Purpose: As the most common subset of breast cancer (BC), estrogen receptor positive (ER+) BC accounting for 80% of cases, has become a global public health concern. The female hormone estrogen (E2) unequivocally drives ER + breast malignancies. The
Externí odkaz:
https://doaj.org/article/df17b2a70be748dab3f7c10b582ab3f3
Publikováno v:
BMC Complementary Medicine and Therapies, Vol 23, Iss 1, Pp 1-17 (2023)
Abstract Most of the breast cancers are estrogen receptor-positive recurring with a steady rate of up to 20 years dysregulating the normal cell cycle. Dinaciclib is still in clinical trials and considered as a research drug against such cancers targe
Externí odkaz:
https://doaj.org/article/f93741f067be4676b74fe9081dad3cfc
Publikováno v:
陆军军医大学学报, Vol 45, Iss 19, Pp 2065-2073 (2023)
Objective To investigate the mechanism of celastrol (Cel) against estrogen receptor positive (ER+) breast cancer by activating endoplasmic reticulum stress-mediated apoptosis. Methods ER+ human breast cancer cell lines MCF-7 and T47D were used as res
Externí odkaz:
https://doaj.org/article/c4cbce426bcc4d7ab12752de3d63f6af
Publikováno v:
Frontiers in Immunology, Vol 14 (2024)
In ER+ breast cancer, usually seen as the low immunogenic type, the main mechanisms favouring the immune response or tumour growth and immune evasion in the tumour microenvironment (TME) have been examined. The principal implications of targeting the
Externí odkaz:
https://doaj.org/article/fc7e92300b164142bf94b70243e79636
Autor:
Neil Carleton, Julia Foldi
Publikováno v:
Frontiers in Medicine, Vol 10 (2024)
The CDK4/6 inhibitor, abemaciclib, is now the standard of care adjuvant therapy for patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) tumors at high risk of recurrence. Real-world usage uncovers
Externí odkaz:
https://doaj.org/article/6d7a3a770e474a03ae07ee48711ba621
Autor:
Kathleen A. O’Leary, Amber M. Bates, Won Jong Jin, Brian M. Burkel, Raghava N. Sriramaneni, Sarah E. Emma, Erin J. Nystuen, Elizabeth G. Sumiec, Suzanne M. Ponik, Zachary S. Morris, Linda A. Schuler
Publikováno v:
Breast Cancer Research, Vol 25, Iss 1, Pp 1-15 (2023)
Abstract Background Most patients with estrogen receptor positive (ER+) breast cancer do not respond to immune checkpoint inhibition (ICI); the tumor microenvironment (TME) of these cancers is generally immunosuppressive and contains few tumor-infilt
Externí odkaz:
https://doaj.org/article/ed62145c75cf435aa09efab35a43623c
Publikováno v:
Current Oncology, Vol 30, Iss 2, Pp 1794-1804 (2023)
Approximately 80% of breast cancers are estrogen receptor-positive (ER+), and 68–80% of those occur in premenopausal or perimenopausal women. Since the introduction of tamoxifen for adjuvant endocrine therapy in women with non-metastatic ER+ breast
Externí odkaz:
https://doaj.org/article/9f507757acda43348f6698b3e12bdc85
Autor:
Hui‐Ping Hsu, Pei‐Yi Chu, Tsung‐Ming Chang, Kuo‐Wei Huang, Wen‐Chun Hung, Shih Sheng Jiang, Hui‐You Lin, Hui‐Jen Tsai
Publikováno v:
Cancer Medicine, Vol 12, Iss 2, Pp 1588-1601 (2023)
Abstract Background Tumor cells may aberrantly express metabolic enzymes to adapt to their environment for survival and growth. Targeting cancer‐specific metabolic enzymes is a potential therapeutic strategy. Phosphoenolpyruvate carboxykinase (PEPC
Externí odkaz:
https://doaj.org/article/95aa146bb8eb4a7c8ac27962dfcfb6c6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.